A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : FCM / ferric carboxymaltose

[Related PubMed/MEDLINE]
Total Number of Papers: 126
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   FCM  (>> Co-occurring Abbreviation)
Long Form:   ferric carboxymaltose
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment. GI, IDA, IIM, ITC, RCTs, SLR
2019 Clinical experience with ferric carboxymaltose in the management of anemia in acute gastrointestinal bleeding. AGIB, Hb
2019 Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for the treatment of preoperative anemia in patients with menorrhagia: An open-label, multicenter, randomized study. Hb, IDA, IS, QOL
2019 Comparison of efficacy and safety between intravenous ferric carboxymaltose and saccharated ferric oxide in Japanese patients with iron-deficiency anemia due to hypermenorrhea: a multi-center, randomized, open-label noninferiority study. IDA, SFO
2019 Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing. TSAT
2019 Ferric carboxymaltose in the treatment of iron deficiency in pediatric inflammatory bowel disease. CRP, Hb, IBD, ID, IDA, MCV, ORs, TS
2019 Iron-deficiency anemia reduces cardiac contraction by downregulating RyR2 channels and suppressing SERCA pump activity. HF, SR
2019 Pharmacokinetics of ferric bepectate-a new intravenous iron drug for treating iron deficiency. FBP
2019 Safety and efficacy of intravenous ferric carboxymaltose in Japanese patients with iron-deficiency anemia caused by digestive diseases: an open-label, single-arm study. IDA
10  2019 [Assessment of iron deficiency anemia management in the general hospital of Grenoble: A 12-month follow-up of an intravenous ferric carboxymaltose treatment program in a cohort of patients with non-dialysis-dependent chronic kidney disease]. ESA, Hb, ND-CKD, TSAT
11  2018 A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy. CKD, FEPi, FGF23, TSAT
12  2018 A Prospective Randomised Controlled Trial of a Single Intravenous Infusion of Ferric Carboxymaltose vs Single Intravenous Iron Polymaltose or Daily Oral Ferrous Sulphate in the Treatment of Iron Deficiency Anaemia in Pregnancy. Hb, IDA, IPM, QOL, RCT
13  2018 Assessing the costs and benefits of perioperative iron deficiency anemia management with ferric carboxymaltose in Germany. IDA
14  2018 Changes in myocardial iron content following administration of intravenous iron (Myocardial-IRON): Study design. Myocardial-IRON
15  2018 Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial. HSRs, IDA
16  2018 Effectiveness and safety of ferric carboxymaltose compared to iron sucrose in women with iron deficiency anemia: phase IV clinical trials. Hb, IDA, IS
17  2018 Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. CI, CV, HF, ID, RCTs
18  2018 Efficacy and safety of ferric carboxymaltose versus ferrous sulfate for iron deficiency anemia during pregnancy: subgroup analysis of Korean women. FS, Hb, IDA, QOL
19  2018 Efficacy of ferric carboxymaltose (FCM) 500mg dose for the treatment of Restless Legs Syndrome. IRLSS, RLS, VAS
20  2018 Extreme anemia (Hb 33 g/L) in a 13-year-old girl: Is the transfusion always mandatory? ---
21  2018 Financial impact of intravenous iron treatments on the management of anaemia inpatients: a 1year observational study. IDA, IS
22  2018 Impact of ferric carboxymaltose on the evolution of hemoglobin and ECOG performance status in iron-deficient patients with solid tumors: a 3-month follow-up retrospective study. ---
23  2018 Improved Hemoglobin Response with Ferric Carboxymaltose in Patients with Gastrointestinal-Related Iron-Deficiency Anemia Versus Oral Iron. GI, Hb, IDA, SAEs, TSAT
24  2018 Iron Deficiency Anemia with Menorrhagia: Ferric Carboxymaltose a Safer Alternative to Blood Transfusion. Hb, IDA
25  2018 Iron deficiency without anemia is responsible for decreased left ventricular function and reduced mitochondrial complex I activity in a mouse model. ID, ID
26  2018 Pharmacokinetics, pharmacodynamics, safety, and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in Japanese volunteers with iron-deficiency anemia. IDA, PD, PK
27  2018 Retrospective cohort study comparing the adverse reactions and efficacy of intravenous iron polymaltose with ferric carboxymaltose for iron deficiency anemia. ADRs
28  2018 Role of intravenous iron in the treatment of anemia in patients with gastrointestinal tract tumors undergoing chemotherapy: a single-center, observational study. ---
29  2018 Safety and Efficacy of Ferric Carboxymaltose in the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease, in Routine Daily Practice. AEs, CD, Hb, IBD, s-ferritin, SAEs, UC
30  2018 Safety and efficacy of intravenous iron polymaltose, iron sucrose and ferric carboxymaltose in pregnancy: A systematic review. IDA, IPM, IS, RCTs
31  2018 Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice. CHF, ESC, HFrEF
32  2018 Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration. FGF23
33  2018 Single-dose intravenous iron in Southeast Asian heart failure patients: A pilot randomized placebo-controlled study (PRACTICE-ASIA-HF). 6MWT, CI, HF, KCCQ, VAS
34  2018 Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients. HD, IS
35  2017 Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany. HF, ID, NYHA
36  2017 Cardiovascular, liver, and renal toxicity associated with an intravenous ferric carboxymaltose similar versus the originator compound. FCMS
37  2017 Comparative safety of intravenous Ferumoxytol versus Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia: rationale and study design of a randomized double-blind study with a focus on acute hypersensitivity reactions. AEs
38  2017 Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions. HP, HSRs
39  2017 Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. HF
40  2017 Effect of ferric carboxymaltose on hospitalization and mortality outcomes in chronic heart failure: A meta-analysis. CHF, CI, CV, RR
41  2017 Efficacy and Tolerability of Intravenous Ferric Carboxymaltose in Patients with Iron Deficiency at a Hospital Outpatient Clinic: A Retrospective Cohort Study of Real-World Clinical Practice. CI, OR
42  2017 Ferric Carboxymaltose as Treatment in Women with Iron-Deficiency Anemia. AE, IDA, SMC
43  2017 Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: an international, open-label, randomized controlled trial (FER-ASAP). CI, FS, Hb, IDA, OR
44  2017 Ferric carboxymaltose-induced hypophosphataemia after kidney transplantation. CKD, FGF23
45  2017 Intravenous Ferric Carboxymaltose in Children with Iron Deficiency Anemia Who Respond Poorly to Oral Iron. IDA
46  2017 Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK. IBD, IIM, IS, LMWID
47  2017 Markers of oxidative/nitrosative stress and inflammation in lung tissue of rats exposed to different intravenous iron compounds. FMX, IS, LMWID
48  2017 Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial. ND-CKD, SE
49  2017 Retrospective review of effectiveness and safety of intravenous ferric carboxymaltose given to children with iron deficiency anaemia in one UK tertiary centre. ---
50  2017 Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial. CKD
51  2017 The effectiveness of intravenous iron for iron deficiency anemia in gastrointestinal cancer patients: a retrospective study. DIO, Hb, ID, IQR
52  2017 Use of iron sucrose and red blood cell transfusions in anaemic cancer patients in France (OncoFer study). IS, RBC
53  2016 Assessment of serum bioactive hepcidin-25, soluble transferrin receptor and their ratio in predialysis patients: Correlation with the response to intravenous ferric carboxymaltose. sTfR
54  2016 Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk. ---
55  2016 Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. IRLSS, RLS, VAS
56  2016 Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France. Hb
57  2016 Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose or oral iron as preoperative treatment in patients with colon cancer and iron deficiency anaemia. IS, OI
58  2016 Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial. cFGF23, FGF23, iFGF23, IS
59  2016 Ferric carboxymaltose reduces the number of red blood cell units transfused and allows transfusion independence to be obtained in patients with iron deficiency anemia secondary to gastrointestinal chronic blood loss. CBL, Hb, IDA, RBC, TSAT
60  2016 Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. CC, RBC
61  2016 Ferric carboxymaltose with or without erythropoietin in anemic patients with hip fracture: a randomized clinical trial. EPO, EPO, Hb, HF, RBC
62  2016 Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial. ND-CKD, TSAT
63  2016 Impact of individual intravenous iron preparations on the differentiation of monocytes towards macrophages and dendritic cells. i.v, IS, mDCs, miRNA, SFG
64  2016 Implementing a blood management protocol during the entire perioperative period allows a reduction in transfusion rate in major orthopedic surgery: a before-after study. EPO, PBM
65  2016 Intravenous iron administration in restless legs syndrome : An observational study in geriatric patients. ADL, i.v, IRLS, RLS, TFS
66  2016 IV Ferric Carboxymaltose Vs Oral Iron in the Treatment of Post-partum Iron Deficiency Anaemia. Hb, IDA
67  2016 Left ventricular ejection fraction recovery in patients with heart failure treated with intravenous iron: a pilot study. CMR, HFrEF, LVEF
68  2016 Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding. AUB, ISC
69  2016 Rationale and design of a pilot randomized controlled trial to assess the role of intravenous ferric carboxymaltose in Asian patients with heart failure (PRACTICE-ASIA-HF). HF, i.v, ID
70  2016 Rationale and design of a pilot randomized controlled trial to assess the role of intravenous ferric carboxymaltose in Asian patients with heart failure (PRACTICE-ASIA-HF). HF, i.v, ID
71  2016 The role of ferric carboxymaltose in the treatment of iron deficiency anemia in patients with gastrointestinal disease. IDA
72  2015 Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden. CHF, HRQoL, ICER, QALYs
73  2015 Ferric carboxymaltose: A revolution in the treatment of postpartum anemia in Indian women. Hb
74  2015 Intravenous Iron Therapy in Patients with Iron Deficiency Anemia: Dosing Considerations. IDA, IS
75  2015 Iron sucrose and ferric carboxymaltose: no correlation between physicochemical stability and biological activity. IS, LIP
76  2015 Open-label study of the efficacy and safety of intravenous ferric carboxymaltose in pregnant women with restless legs syndrome. Hb, IRLS, RLS
77  2015 Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose. FMX, IS, LMWID, SFG
78  2015 Safety and Efficacy of Ferric Carboxymaltose in Anemic Pregnant Women: A Retrospective Case Control Study. ---
79  2015 Safety of ferric carboxymaltose immediately after infliximab administration, in a single session, in inflammatory bowel disease patients with iron deficiency: a pilot study. AEs, IBD, IFX, IRA, pre-FCM
80  2015 The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study. CHF, CKD-EPI
81  2015 The safety and efficacy of high dose ferric carboxymaltose in patients with chronic kidney disease: A single center study. CKD
82  2015 TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose. FG, ID, IDA, LA
83  2015 [Clinical experience with ferric carboxymaltose in non-dialysis chronic kidney disease]. ND-CKD
84  2014 A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Hb, IDA, SD, SD
85  2014 Cost-utility of ferric carboxymaltose (Ferinject) for iron-deficiency anemia patients with chronic heart failure in South Korea. CHF, ICER, IDA, NYHA, QALY
86  2014 Effectiveness and safety of ferric carboxymaltose treatment in children and adolescents with inflammatory bowel disease and other gastrointestinal diseases. ---
87  2014 Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women--PREFER a randomized, placebo-controlled study. PFS
88  2014 Experience with intravenous ferric carboxymaltose in patients with iron deficiency anemia. IDA
89  2014 Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. NDD-CKD
90  2014 Ferric carboxymaltose-mediated attenuation of Doxorubicin-induced cardiotoxicity in an iron deficiency rat model. AIC, BW, IDA, SHRSP
91  2014 FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. CI, CKD, ESAs, Hb, HR, HR
92  2014 Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose. NDD-CKD
93  2014 Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients. CKD, ESA, GPx, OS, TSAT
94  2014 Randomized trial comparing ferric carboxymaltose vs oral ferrous glycine sulphate for postoperative anaemia after total knee arthroplasty. FS, Hb, TKA
95  2014 Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. 6MWT, CHF, Hb, ID, NYHA, TSAT
96  2014 The FIND-CKD study--a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale. ESA, Hb, ND-CKD
97  2013 Acute and sub-acute effect of ferric carboxymaltose on inflammation and adhesion molecules in patients with predialysis chronic renal failure. CKD, CRP, ICAM, IL-6, VCAM
98  2013 An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic. CKD-ND, IS
99  2013 Anemia and iron deficiency in inflammatory bowel disease: an open, prospective, observational study on diagnosis, treatment with ferric carboxymaltose and quality of life. CD, IBD, UC
100  2013 Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. ESAs, Hb, i.v